Pediatrix Medical Group (MD) Expected to Release Earnings on Tuesday

Pediatrix Medical Group (NYSE:MD) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.57 per share and revenue of $478.4860 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. Pediatrix Medical Group’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 earnings per share. On average, analysts expect Pediatrix Medical Group to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $26.13 on Tuesday. The company has a 50 day moving average of $24.24 and a 200 day moving average of $22.37. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. The stock has a market cap of $2.15 billion, a P/E ratio of 12.69 and a beta of 0.66. Pediatrix Medical Group has a 12 month low of $11.84 and a 12 month high of $27.94.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total transaction of $855,665.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.80% of the stock is owned by insiders.

Institutional Trading of Pediatrix Medical Group

Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in Pediatrix Medical Group by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,569,219 shares of the company’s stock valued at $76,349,000 after buying an additional 169,441 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pediatrix Medical Group by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock valued at $46,674,000 after acquiring an additional 14,421 shares during the last quarter. Boston Partners boosted its holdings in Pediatrix Medical Group by 0.6% during the 3rd quarter. Boston Partners now owns 1,427,953 shares of the company’s stock valued at $24,063,000 after acquiring an additional 8,335 shares during the period. Renaissance Technologies LLC boosted its holdings in Pediatrix Medical Group by 4.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,357,700 shares of the company’s stock valued at $29,041,000 after acquiring an additional 51,700 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Pediatrix Medical Group by 55.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock worth $19,150,000 after acquiring an additional 407,780 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on MD shares. UBS Group raised their price target on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research note on Friday, May 8th. Truist Financial boosted their target price on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.33.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.